- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01042938
Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients
June 19, 2012 updated by: Julie Ryan, University of Rochester
Ionizing radiation is a toxic agent and widely accepted form of treatment for various types of cancer.
Despite advances in medical technology, radiation therapy still causes severe early and late skin effects.
Radiation-induced dermatitis occurs in approximately 80% of patients.
Important consequences of radiation-induced dermatitis include impairment of the quality of a patient's life due to pain and premature interruption of radiation treatment, which in turn, may be impair good local control of disease.
The biological pathways responsible for acute radiation-induced dermatitis remain unclear.
Currently, there is no standard treatment for the prevention of radiation-induced dermatitis with demonstrated effectiveness.
The aim of this randomized, double-blind, placebo-controlled pilot study is to assess the effectiveness of curcumin for the prevention of acute radiation-induced dermatitis during postoperative radiotherapy for breast cancer.
We hypothesize that curcumin, a natural phenolic compound found in both turmeric and curry powders, can prevent or alleviate radiation-induced skin reactions in breast cancer patients receiving radiotherapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Specifically, this clinical pilot study will develop data necessary to calculate a sample size for a larger study to be conducted through the National Cancer Institute (NCI) Community Clinical Oncology Program (CCOP) mechanism.
Specifically, this pilot project will investigate: 1) if curcumin can prevent or alleviate radiation-induced skin reactions in cancer patients receiving radiotherapy and 2) if skin pigmentation, as well as pain and psychophysiological factors, can predict the severity of radiation-induced dermatitis.
Potential future research studies may be conducted to identify the biological mechanisms involved in radiation-induced dermatitis and the radioprotective function of curcumin.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center & Wilmot Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy.
- Participants must be at least 21 years of age.
- Participants must not be pregnant.
- Participants can be from any racial or ethnic origin.
- Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.
- Participants with in situ breast cancer are eligible.
- Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible.
- Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation.
- A time period of three weeks must elapse after chemotherapy and surgery before beginning the study.
- The total dose prescribed to the whole breast should be 50 Gy or greater.
- Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).
- Participants must be able to swallow medication.
- Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically.
- Participant must give informed consent.
Exclusion Criteria:
- Patients with bilateral breast cancer are not eligible.
- Patients who have had previous radiation therapy to the breast or chest are not eligible.
- Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible.
- Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible.
- Patients cannot have had breast reconstructions, implants, and/or expanders.
- Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible.
- Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible.
- Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Curcumin C3 Complex
Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
|
Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
|
Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients
Time Frame: 4-7 weeks (prescribed course of radiation)
|
The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5.
The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin.
The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group.
Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm.
|
4-7 weeks (prescribed course of radiation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Moist Desquamation at Radiation Treatment Site
Time Frame: 4-7 weeks (prescribed course of radiation)
|
The presence of moist desquamation at the end of radiation treatment was examined between curcumin and placebo treatment groups.
We compared the number of participants (or percentage) with moist desquamation between each treatment group.
|
4-7 weeks (prescribed course of radiation)
|
Redness at Radiation Treatment Site
Time Frame: 4-7 weeks (prescribed course of radiation)
|
Redness at radiation treatment site was measured using a CR-400 Colorimeter (Konica Minolta).
The colorimeter uses the L*a*b* color scale.
We used a* values (redness) which range from 0.0 to 20.0.
The lower the number value, the lower amount of redness.
Therefore, high number values represent large amounts of redness.
|
4-7 weeks (prescribed course of radiation)
|
Pain at Radiation Treatment Site
Time Frame: 4-7 weeks (prescribed course of radiation)
|
The McGill Pain Questionnaire-Short Form (MPQ-SF) was used to determine the participants pain at treatment site.
The MPQ-SF contains three subscales: affective pain, sensory pain, and perceived pain.
This outcome measure compared the total pain score (range 0 to 50)and subscale scores (sensory subscale range 0 to 33; affective subscale range 0 to 12; perceived pain subscale 0 to 5) at the end of radiation therapy between the two treatment arms.
|
4-7 weeks (prescribed course of radiation)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Julie L Ryan, PhD, MPH, University of Rochester Medical Center & Wilmot Cancer Center
- Study Chair: Julie L Ryan, PhD, MPH, University of Rochester Medical Center & Wilmot Cancer Center
- Study Chair: Alice P Pentland, MD, University of Rochester Medical Center & Wilmot Cancer Center
- Study Chair: Marilyn Ling, MD, University of Rochester Medical Center & Wilmot Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (ACTUAL)
September 1, 2010
Study Completion (ACTUAL)
April 1, 2011
Study Registration Dates
First Submitted
January 4, 2010
First Submitted That Met QC Criteria
January 5, 2010
First Posted (ESTIMATE)
January 6, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
June 25, 2012
Last Update Submitted That Met QC Criteria
June 19, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Breast Diseases
- Radiation Injuries
- Breast Neoplasms
- Dermatitis
- Radiodermatitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- URCC1106
- 5KL2RR024136-03 (NIH)
- 05-238-80 (OTHER_GRANT: Dermatology Foundation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Curcumin C3 Complex
-
University of LeicesterCompletedMetastasis | Colonic CancerUnited Kingdom
-
Daniel DobererCompleted
-
Louisiana State University Health Sciences Center...National Cancer Institute (NCI); Feist-Weiller Cancer Center at Louisiana State...Completed
-
University of RochesterNational Cancer Institute (NCI)CompletedRadiation-induced Dermatitis
-
Nita Chainani WuCompletedOral Lichen PlanusUnited States
-
University of RochesterRecruitingMultiple Myeloma | Prostate Cancer | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma (SMM)United States
-
John Douglas French FoundationInstitute for the Study of Aging (ISOA)Completed
-
Lisa FlowersNot yet recruiting
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditionsUnited States